Effects of High Dose Interferon-β1a on Plasma Microparticles in MS
Author Information
Author(s): Mary Lowery-Nordberg, Erin Eaton, Eduardo Gonzalez-Toledo, Meghan K Harris, Kathrine Chalamidas, Jeanie McGee-Brown, Chaitanya V Ganta, Alireza Minagar, David Cousineau, Steven J Alexander
Primary Institution: LSU Health Sciences Center-Shreveport
Hypothesis
Prospective serial measurement of three sub-species of PMP CD31+, PMPCD146+, and PMPCD54+ may reflect disease activity and serve as a surrogate marker of therapeutic response to high dose, high frequency interferon-β1a.
Conclusion
The study suggests that measuring plasma microparticles may serve as reliable markers of response to interferon-β1a therapy in MS patients.
Supporting Evidence
- Plasma levels of PMPCD31+ and PMPCD54+ were significantly reduced by treatment with IFN-β1a.
- The decrease in plasma levels of PMPCD31+ and PMPCD54+ at 12 months was associated with a significant decrease in MRI lesions.
- CD54+ microparticles were statistically significantly reduced at 3, 6, and 12 months after treatment.
Takeaway
This study looked at how a medicine called interferon-β1a affects tiny particles in the blood of people with multiple sclerosis, finding that the medicine helps lower these particles over time.
Methodology
A one-year prospective study measuring plasma microparticles in patients with relapsing-remitting MS before and after treatment with interferon-β1a.
Potential Biases
Potential bias due to lack of a control group and the subjective nature of clinical assessments.
Limitations
The study did not include an untreated control group, and the effects of individual variations in patient responsiveness were noted.
Participant Demographics
Mean age of participants was 31 years, with 14 females and 2 males.
Statistical Information
P-Value
0.0511
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website